Search

Displaying results 1811 - 1820 of 10000 in total
  1. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

  2. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib is currently under investigation for use in many other forms of cancer. … Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. … The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge.

  4. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.

  5. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia.

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  6. Drug

    Oxprenolol

    go.drugbank.com/drugs/DB01580
    ApprovedWithdrawn

    A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

  7. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    and/or Asia. … It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.

  8. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

    Products: VISTAGAN LIQUIFILM 0.5%O K
  9. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated

    Categories: Antivirals for treatment of HCV infections
  10. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine … Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with